英国临床医生对应用分子诊断指导ICU肺炎患者抗生素使用的态度:一项定量研究
该研究于2020年5月至7月对英国5家医院的63名ICU临床医生进行横断面问卷调查,评估其对分子诊断用于指导初始用药和早期停用广谱抗生素的态度。83%的受访者对分子诊断持积极态度,认为利用结果指导广谱抗生素处方是良好实践,但58%认为病情严重的患者常过于不稳定,难以根据阴性结果冒险停用广谱抗生素。
要点
- 83%的ICU临床医生对分子诊断用于指导广谱抗生素处方持积极态度。
- 58%的ICU临床医生认为病情严重的患者常过于不稳定,难以根据阴性结果停用广谱抗生素。
- 临床医生对分子诊断指导初始治疗和早期停用广谱抗生素的态度存在细微差别。
核心结论
- 临床医生对应用分子诊断改善抗生素管理的积极态度与认为需要启动和维持广谱抗生素以保护不稳定患者的看法并存。
研究设计与样本
- 横断面问卷调查,于2020年5月至2020年7月期间,来自英国5家医院的63名ICU临床医生完成了问卷。
主要发现
- 83%的受访者对分子诊断持积极态度,同意利用结果指导广谱抗生素处方是良好实践。
- 58%的受访者认为病情严重的患者常过于不稳定,难以根据阴性结果冒险停用广谱抗生素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Molecular diagnostic tests may improve antibiotic prescribing by enabling earlier tailoring of antimicrobial therapy. However, clinicians' trust and acceptance of these tests will determine their application in practice. OBJECTIVES: To examine ICU prescribers' views on the application of molecular diagnostics in patients with suspected hospital-acquired and ventilator-associated pneumonia (HAP/VAP). METHODS: Sixty-three ICU clinicians from five UK hospitals completed a cross-sectional questionnaire between May 2020 and July 2020 assessing attitudes towards using molecular diagnostics to inform initial agent choice and to help stop broad-spectrum antibiotics early. RESULTS: Attitudes towards using molecular diagnostics to inform initial treatment choices and to stop broad-spectrum antibiotics early were nuanced. Most (83%) were positive about molecular diagnostics, agreeing that using results to inform broad-spectrum antibiotic prescribing is good practice. However, many (58%) believed sick patients are often too unstable to risk stopping broad-spectrum antibiotics based on a negative result. CONCLUSIONS: Positive attitudes towards the application of molecular diagnostics to improve antibiotic stewardship were juxtapositioned against the perceived need to initiate and maintain broad-spectrum antibiotics to protect unstable patients.
引用
- Stewart SF, Pandolfo AM, Moon Z, et al. UK clinicians' attitudes towards the application of molecular diagnostics to guide antibiotic use in ICU patients with pneumonias: a quantitative study. J Antimicrob Chemother. 2024. PMID: 37970680. doi:10.1093/jac/dkad355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。